...
...
Next Story

Steyn failed drug test during 2nd IPL: CSA

South African fast bowler Dale Steyn failed a drug test as a result of taking painkillers to recover from an injury during the second Indian Premier League, his cricket board said on Tuesday.

Updated on: Aug 11, 2009 04:52 PM IST
PTI | By , Johannesburg
Prefer HTon Google
Advertisement

South African fast bowler Dale Steyn failed a drug test as a result of taking painkillers to recover from an injury during the second Indian Premier League, his cricket board said on Tuesday.

HT Image
HT Image

Cricket South Africa Chief Executive Gerald Majola said Steyn was found to have morphine level slightly above the normal because of the painkillers he took and CSA has submitted a report in this regard to the IPL authorities.

"We are aware of the result and submitted a report immediately to the IPL on why this has happened," Majola said.

"There was a marginal increase in the presence of morphine in the sample and that was due to painkillers he took during that period. We are awaiting a reply from the IPL authorities," he told Cricinfo.

Steyn was out of action for most of the IPL in South Africa in April-May due to a thumb injury and played only three matches for Bangalore Royal Challengers.

"This is not a doping violation as such but an adverse analytical finding, which is different," Moosajee said.

"Dale is known to have a history of chronic migraines and he suffered a thumb injury too during the IPL and he was on Myprodol, a painkiller that contains codeine", he said.

 
Get the Cricket Live Score! including IPL Matches and track ICC rankings shifts, Cricket Schedule, and Players Stats along with detailed score profiles of Virat Kohli, Rohit Sharma, Shubman Gill.
Get the Cricket Live Score! including IPL Matches and track ICC rankings shifts, Cricket Schedule, and Players Stats along with detailed score profiles of Virat Kohli, Rohit Sharma, Shubman Gill.
SHARE THIS ARTICLE ON
Hindustantimes wants to start sending you push notifications. Click allow to subscribe